{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:17:33Z","timestamp":1771510653900,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0502200"],"award-info":[{"award-number":["2023ZD0502200"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373514"],"award-info":[{"award-number":["82373514"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02226-7","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:48:51Z","timestamp":1769593731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy"],"prefix":"10.1186","volume":"28","author":[{"given":"Fei-Fei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Yu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Xiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Fu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"6","key":"2226_CR1","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"issue":"32","key":"2226_CR2","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/JCO.2013.49.5077","volume":"31","author":"M Donker","year":"2013","unstructured":"Donker M, Liti\u00e8re S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054\u20139.","journal-title":"J Clin Oncol"},{"issue":"32","key":"2226_CR3","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","volume":"32","author":"F W\u00e4rnberg","year":"2014","unstructured":"W\u00e4rnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol. 2014;32(32):3613\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2226_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21\u20139.","journal-title":"Lancet Oncol"},{"key":"2226_CR5","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative G, Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L et al: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010, 2010(41):162\u2013177.","DOI":"10.1093\/jncimonographs\/lgq039"},{"issue":"10","key":"2226_CR6","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1016\/S1470-2045(16)30367-9","volume":"17","author":"JR Benson","year":"2016","unstructured":"Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Lancet Oncol. 2016;17(10):e442\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2226_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/1055-9965.EPI-18-0976","volume":"28","author":"LL Visser","year":"2019","unstructured":"Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol Biomarkers Prev. 2019;28(5):835\u201345.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"2226_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7(10):1098\u2013115.","journal-title":"Cancer Discov"},{"issue":"1","key":"2226_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2226_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-20-3299","volume":"27","author":"A Stenmark Tullberg","year":"2021","unstructured":"Stenmark Tullberg A, Puttonen HAJ, Sj\u00f6str\u00f6m M, Holmberg E, Chang SL, Feng FY, et al. Immune infiltrate in the primary tumor predicts effect of adjuvant radiotherapy in breast cancer; results from the randomized SweBCG91RT trial. Clin Cancer Res. 2021;27(3):749\u201358.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2226_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.18.02157","volume":"37","author":"A Kov\u00e1cs","year":"2019","unstructured":"Kov\u00e1cs A, Stenmark Tullberg A, Werner R\u00f6nnerman E, Holmberg E, Hartman L, Sj\u00f6str\u00f6m M, et al. Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial. J Clin Oncol. 2019;37(14):1179\u201387.","journal-title":"J Clin Oncol"},{"key":"2226_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1875637","author":"F-F Xu","year":"2021","unstructured":"Xu F-F, Zheng S-F, Xu C, Cai G, Wang S-B, Qi W-X, et al. Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ. Oncoimmunology. 2021. https:\/\/doi.org\/10.1080\/2162402X.2021.1875637.","journal-title":"Oncoimmunology"},{"key":"2226_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.breast.2022.04.004","volume":"64","author":"F Darvishian","year":"2022","unstructured":"Darvishian F, Wu Y, Ozerdem U, Chun J, Adams S, Guth A, et al. Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ. Breast. 2022;64:35\u201340.","journal-title":"Breast"},{"issue":"1","key":"2226_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","volume":"177","author":"X-Y Chen","year":"2019","unstructured":"Chen X-Y, Yeong J, Thike AA, Bay BH, Tan PH. Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treat. 2019;177(1):17\u201327.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2226_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.14055","volume":"76","author":"AA Thike","year":"2020","unstructured":"Thike AA, Chen X, Koh VCY, Binte Md Nasir ND, Yeong JPS, Bay BH, et al. Higher densities of tumour\u2010infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast. Histopathology. 2020;76(6):852\u201364.","journal-title":"Histopathology"},{"key":"2226_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09883-9","author":"S-L Wu","year":"2022","unstructured":"Wu S-L, Yu X, Mao X, Jin F. Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis. BMC Cancer. 2022. https:\/\/doi.org\/10.1186\/s12885-022-09883-9.","journal-title":"BMC Cancer"},{"issue":"8","key":"2226_CR17","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","volume":"20","author":"G Di Caro","year":"2014","unstructured":"Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res. 2014;20(8):2147\u201358.","journal-title":"Clin Cancer Res"},{"issue":"6576","key":"2226_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419.","journal-title":"Science"},{"issue":"8","key":"2226_CR19","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1016\/j.clbc.2022.08.005","volume":"22","author":"E Acar","year":"2022","unstructured":"Acar E, Esenda\u011fl\u0131 G, Yaz\u0131c\u0131 O, Dursun A. Tumor-infiltrating lymphocytes (TIL), tertiary lymphoid structures (TLS), and expression of PD-1, TIM-3, LAG-3 on TIL in invasive and in situ ductal breast carcinomas and their relationship with prognostic factors. Clin Breast Cancer. 2022;22(8):e901\u201315.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"2226_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10549-020-05548-y","volume":"180","author":"DYB Seow","year":"2020","unstructured":"Seow DYB, Yeong JPS, Lim JX, Chia N, Lim JCT, Ong CCH, et al. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. Breast Cancer Res Treat. 2020;180(2):369\u201377.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2226_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jclinpath-2015-203089","volume":"69","author":"HJ Lee","year":"2016","unstructured":"Lee HJ, Park IA, Song IH, Shin S-J, Kim JY, Yu JH, et al. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol. 2016;69(5):422\u201330.","journal-title":"J Clin Pathol"},{"issue":"17","key":"2226_CR22","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.3390\/jcm11175188","volume":"11","author":"F Xu","year":"2022","unstructured":"Xu F, Cao L, Xu C, Cai G, Cai R, Qi W, et al. A novel nomogram for predicting prognosis and tailoring local therapy decision for ductal carcinoma in situ after breast conserving surgery. J Clin Med. 2022;11(17):5188.","journal-title":"J Clin Med"},{"issue":"9","key":"2226_CR23","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.7150\/jca.39509","volume":"11","author":"Y Fang","year":"2020","unstructured":"Fang Y, Wang Z, Wu J, Huang O, He J, Zhu L, et al. Factors influencing adjuvant chemotherapy and trastuzumab choice in older human epidermal growth factor receptor 2-positive breast cancer patients. J Cancer. 2020;11(9):2602\u20139.","journal-title":"J Cancer"},{"issue":"10","key":"2226_CR24","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41416-020-0797-7","volume":"122","author":"MS Toss","year":"2020","unstructured":"Toss MS, Abidi A, Lesche D, Joseph C, Mahale S, Saunders H, et al. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. Br J Cancer. 2020;122(10):1496\u2013506.","journal-title":"Br J Cancer"},{"issue":"8","key":"2226_CR25","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","volume":"31","author":"MS Toss","year":"2018","unstructured":"Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, et al. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol. 2018;31(8):1226\u201336.","journal-title":"Mod Pathol"},{"issue":"1","key":"2226_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1875637","volume":"10","author":"FF Xu","year":"2021","unstructured":"Xu FF, Zheng SF, Xu C, Cai G, Wang SB, Qi WX, et al. Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ. Oncoimmunology. 2021;10(1):1875637.","journal-title":"Oncoimmunology"},{"key":"2226_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022. https:\/\/doi.org\/10.1126\/science.abf9419.","journal-title":"Science"},{"issue":"5","key":"2226_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100063","volume":"103","author":"L Vanhersecke","year":"2023","unstructured":"Vanhersecke L, Bougouin A, Cromb\u00e9 A, Brunet M, Sofeu C, Parrens M, et al. Standardized pathology screening of mature tertiary lymphoid structures in cancers. Lab Invest. 2023;103(5):100063.","journal-title":"Lab Invest"},{"key":"2226_CR29","unstructured":"White J, Tai A, Arthur D, Buchholz T, MacDonald S, Marks L, Pierce L, Racht A, Rabinovitch R, Taghian A: Breast cancer atlas for radiation therapy planning: consensus definitions. Book Breast Cancer Atlas for Radiation Therapy Planning 2009."},{"issue":"1","key":"2226_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41379-018-0113-8","volume":"32","author":"M Lee","year":"2019","unstructured":"Lee M, Heo S-H, Song IH, Rajayi H, Park HS, Park IA, et al. Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Mod Pathol. 2019;32(1):70\u201380.","journal-title":"Mod Pathol"},{"key":"2226_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02242-x","author":"N-N Zhang","year":"2021","unstructured":"Zhang N-N, Qu F-J, Liu H, Li Z-J, Zhang Y-C, Han X, et al. Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis. Cancer Cell Int. 2021. https:\/\/doi.org\/10.1186\/s12935-021-02242-x.","journal-title":"Cancer Cell Int"},{"key":"2226_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00256","author":"G Boivin","year":"2018","unstructured":"Boivin G, Kalambaden P, Faget J, Rusakiewicz S, Montay-Gruel P, Meylan E, et al. Cellular composition and contribution of tertiary lymphoid structures to tumor immune infiltration and modulation by radiation therapy. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/fonc.2018.00256.","journal-title":"Front Oncol"},{"issue":"8","key":"2226_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081176","volume":"12","author":"AC Barb","year":"2023","unstructured":"Barb AC, Pasca Fenesan M, Pirtea M, Margan MM, Tomescu L, Melnic E, et al. Tertiary lymphoid structures (TLSs) and stromal blood vessels have significant and heterogeneous impact on recurrence, lymphovascular and perineural invasion amongst breast cancer molecular subtypes. Cells. 2023;12(8):1176.","journal-title":"Cells"},{"key":"2226_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.868155","author":"B Wang","year":"2022","unstructured":"Wang B, Liu J, Han Y, Deng Y, Li J, Jiang Y. The presence of tertiary lymphoid structures provides new insight into the clinicopathological features and prognosis of patients with breast cancer. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.868155.","journal-title":"Front Immunol"},{"issue":"1","key":"2226_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ajcp\/aqw097","volume":"146","author":"A Kim","year":"2016","unstructured":"Kim A, Heo S-H, Kim Y-A, Gong G, Jin Lee H. An examination of the local cellular immune response to examples of both ductal carcinoma in situ (DCIS) of the breast and DCIS with microinvasion, with emphasis on tertiary lymphoid structures and tumor infiltrating lymphoctytes. Am J Clin Pathol. 2016;146(1):137\u201344.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2226_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1378844","volume":"7","author":"F Posch","year":"2018","unstructured":"Posch F, Silina K, Leibl S, M\u00fcndlein A, Moch H, Siebenh\u00fcner A, et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology. 2018;7(2):e1378844.","journal-title":"Oncoimmunology"},{"key":"2226_CR37","unstructured":"Seham A AE-A, Entesar Ali S, Neven M A, Hani E-S, Asmaa M A, Laiche D: Follicular dendritic cells. J Cell Physiol 2021, 237(4)."},{"issue":"7","key":"2226_CR38","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41416-022-01888-2","volume":"127","author":"MM Almekinders","year":"2022","unstructured":"Almekinders MM, Bismeijer T, Kumar T, Yang F, Thijssen B, van der Linden R, et al. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. Br J Cancer. 2022;127(7):1201\u201313.","journal-title":"Br J Cancer"},{"key":"2226_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01267-w","author":"M Kim","year":"2020","unstructured":"Kim M, Chung YR, Kim HJ, Woo JW, Ahn S, Park SY. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020. https:\/\/doi.org\/10.1186\/s13058-020-01267-w.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2226_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0002-9610(03)00265-4","volume":"186","author":"MJ Silverstein","year":"2003","unstructured":"Silverstein MJ. The University of Southern California\/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186(4):337\u201343.","journal-title":"Am J Surg"},{"issue":"23","key":"2226_CR41","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","volume":"28","author":"U Rudloff","year":"2010","unstructured":"Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762\u20139.","journal-title":"J Clin Oncol"},{"issue":"32","key":"2226_CR42","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.21.01083","volume":"39","author":"B McCormick","year":"2021","unstructured":"McCormick B, Winter KA, Woodward W, Kuerer HM, Sneige N, Rakovitch E, et al. Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG Oncology\/RTOG 9804. J Clin Oncol. 2021;39(32):3574\u201382.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2226_CR43","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1245\/s10434-021-09903-1","volume":"28","author":"C Shah","year":"2021","unstructured":"Shah C, Bremer T, Cox C, Whitworth P, Patel R, Patel A, et al. The clinical utility of DCISionRT\u00ae on radiation therapy decision making in patients with ductal carcinoma in situ following breast-conserving surgery. Ann Surg Oncol. 2021;28(11):5974\u201384.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2226_CR44","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/modpathol.2015.79","volume":"28","author":"A Knopfelmacher","year":"2015","unstructured":"Knopfelmacher A, Fox J, Lo Y, Shapiro N, Fineberg S. Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Mod Pathol. 2015;28(9):1167\u201373.","journal-title":"Mod Pathol"},{"issue":"10021","key":"2226_CR45","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","volume":"387","author":"RG Margolese","year":"2016","unstructured":"Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387(10021):849\u201356.","journal-title":"Lancet"},{"key":"2226_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.01.016","volume":"168","author":"A Schiza","year":"2022","unstructured":"Schiza A, Thurfjell V, Stenmark Tullberg A, Olofsson H, Lindberg A, Holmberg E, et al. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. Eur J Cancer. 2022;168:128\u201337.","journal-title":"Eur J Cancer"},{"key":"2226_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01462-z","author":"S Guo","year":"2023","unstructured":"Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C, et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01462-z.","journal-title":"Signal Transduct Target Ther"},{"key":"2226_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06211-2","author":"S Liu","year":"2023","unstructured":"Liu S, Wang W, Hu S, Jia B, Tuo B, Sun H, et al. Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis. 2023. https:\/\/doi.org\/10.1038\/s41419-023-06211-2.","journal-title":"Cell Death Dis"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02226-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:15:56Z","timestamp":1771506956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02226-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02226-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}